Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $36.00

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target upped by Needham & Company LLC from $31.00 to $36.00 in a report published on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on the company. The Goldman Sachs Group upped their price objective on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Mizuho raised their price target on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, November 28th. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Zacks Research downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Finally, HC Wainwright lifted their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $32.14.

Arcutis Biotherapeutics Stock Performance

Shares of NASDAQ:ARQT opened at $26.97 on Thursday. Arcutis Biotherapeutics has a 52 week low of $11.86 and a 52 week high of $31.77. The stock has a market capitalization of $3.35 billion, a P/E ratio of -192.63 and a beta of 1.70. The firm has a fifty day simple moving average of $27.24 and a two-hundred day simple moving average of $23.86. The company has a quick ratio of 3.28, a current ratio of 3.50 and a debt-to-equity ratio of 0.68.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 11.01%. The firm had revenue of $129.50 million for the quarter, compared to analysts’ expectations of $110.79 million. On average, analysts expect that Arcutis Biotherapeutics will post -1.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcutis Biotherapeutics

In related news, insider Larry Todd Edwards sold 2,052 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total value of $52,326.00. Following the completion of the sale, the insider owned 148,865 shares in the company, valued at approximately $3,796,057.50. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Howard G. Welgus sold 10,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.05, for a total value of $250,500.00. Following the transaction, the director directly owned 59,744 shares in the company, valued at $1,496,587.20. The trade was a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 124,656 shares of company stock valued at $3,312,365. 9.40% of the stock is owned by corporate insiders.

Institutional Trading of Arcutis Biotherapeutics

Several hedge funds have recently modified their holdings of the company. Focus Partners Wealth grew its position in shares of Arcutis Biotherapeutics by 0.8% in the 3rd quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after buying an additional 490 shares during the last quarter. Arizona State Retirement System boosted its stake in Arcutis Biotherapeutics by 1.8% in the third quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock valued at $597,000 after acquiring an additional 568 shares in the last quarter. Schroder Investment Management Group grew its holdings in Arcutis Biotherapeutics by 1.1% in the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock worth $1,604,000 after purchasing an additional 594 shares during the last quarter. AlphaQuest LLC grew its holdings in Arcutis Biotherapeutics by 5.7% in the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock worth $238,000 after purchasing an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after purchasing an additional 698 shares in the last quarter.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Solid Q4 results and revenue beat — Arcutis reported a robust Q4 with revenue growth and a GAAP EPS beat, driven by Zoryve adoption; the quarter and raised guidance underpin the bullish view on commercial execution. Arcutis Biotherapeutics surges on earnings beat, raised guidance
• Positive Sentiment: Multiple analyst price-target increases — Needham, TD Cowen and Guggenheim raised targets (to the mid-$30s) and maintain buy ratings, signaling analyst confidence in growth and creating upside narrative for the stock. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Bull case coverage highlights pipeline and label-expansion catalysts — Recent analyst and media pieces emphasize Zoryve market leadership, operating leverage and upcoming pediatric/label catalysts that could support longer-term upside. Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
• Neutral Sentiment: Investor presentation scheduled — Management will present at TD Cowen’s healthcare conference next week, giving investors an opportunity for updated guidance/visibility; this is a near-term catalyst but not an immediate earnings event. Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
• Neutral Sentiment: Broad coverage and transcripts available — Earnings call transcript and multiple recaps give investors transparency into execution and guidance; this helps short- and long-term assessment but is informational. Arcutis (ARQT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Near-term EPS cuts by HC Wainwright — Despite maintaining a Buy and $34 target, HC Wainwright lowered Q2–Q4 2026 EPS estimates, which can temper short-term sentiment and provide a rationale for profit-taking after the post-earnings rally.
• Negative Sentiment: Mixed/unclear short-interest data — Recent short-interest reports appear inconsistent (zero/NaN entries), creating uncertainty about downside pressure from traders; unclear short-covering dynamics can add volatility.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.